MU School of Medicine Participates in Nationwide COVID-19 Drug Study

The University of Missouri School of Medicine Department of Emergency Medicine is joining a nationwide study to evaluate repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19.

Repurposed medications are those that are FDA approved for other indications.

The double-blind study looks to enroll 15,000 patients nationwide.

The three medications being studied are Fluticasone, an inhaled steroid typically used for asthma, Fluvoxamine, typically prescribed for depression, and the anti-parasitic drug Ivermectin.

Study participants must be over 30 years old and have had a positive COVID-19 test in the last 10 days and have suffered from at least two symptoms.

To enroll, visit or call 833-385-1880.

More In COVID-19

Most Recent News